CATX Perspective Therapeutics, Inc.

NYSE isoray.com


$ 3.15 $ -0.08 (-2.51 %)    

Tuesday, 21-Oct-2025 19:53:39 EDT
QQQ $ 610.29 $ -0.16 (-0.03 %)
DIA $ 469.10 $ 2.20 (0.47 %)
SPY $ 670.98 $ -0.01 (0 %)
TLT $ 91.99 $ 0.45 (0.49 %)
GLD $ 376.61 $ -25.91 (-6.43 %)
$ 3.11
$ 3.30
$ 3.03 x 10
$ 3.59 x 100
$ 2.90 - $ 3.46
$ 1.60 - $ 12.90
2,434,928
na
230.96M
$ 1.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-26-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 11-14-2022 09-30-2022 10-Q
12 09-28-2022 06-30-2022 10-K
13 05-12-2022 03-31-2022 10-Q
14 02-09-2022 12-31-2021 10-Q
15 11-10-2021 09-30-2021 10-Q
16 09-27-2021 06-30-2021 10-K
17 05-14-2021 03-31-2021 10-Q
18 02-09-2021 12-31-2020 10-Q
19 11-13-2020 09-30-2020 10-Q
20 09-25-2020 06-30-2020 10-K
21 05-13-2020 03-31-2020 10-Q
22 02-12-2020 12-31-2019 10-Q
23 11-13-2019 09-30-2019 10-Q
24 09-27-2019 06-30-2019 10-K
25 05-10-2019 03-31-2019 10-Q
26 02-13-2019 12-31-2018 10-Q
27 11-09-2018 09-30-2018 10-Q
28 09-26-2018 06-30-2018 10-K
29 05-04-2018 03-31-2018 10-Q
30 02-09-2018 12-31-2017 10-Q
31 11-14-2017 09-30-2017 10-Q
32 09-28-2017 06-30-2017 10-K
33 05-10-2017 03-31-2017 10-Q
34 02-09-2017 12-31-2016 10-Q
35 11-09-2016 09-30-2016 10-Q
36 09-09-2016 06-30-2016 10-K
37 05-10-2016 03-31-2016 10-Q
38 02-09-2016 12-31-2015 10-Q
39 11-09-2015 09-30-2015 10-Q
40 09-14-2015 06-30-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 perspective-therapeutics-reports-44-confirmed-response-rate-and-875-progression-free-patients-treated-with-212pbvmt--net-at-esmo-congress-2025

Updated interim results with an additional ~19 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-t...

 btig-reiterates-buy-on-perspective-therapeutics-maintains-14-price-target

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.

 btig-initiates-coverage-on-perspective-therapeutics-with-buy-rating-announces-price-target-of-14

BTIG analyst Jeet Mukherjee initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Buy rating and announces Pric...

 hc-wainwright--co-reiterates-buy-on-perspective-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $10 pr...

 perspective-therapeutics-announces-first-patient-treated-with-psv359-in-second-cohort-of-phase-12a-dose-finding-trial-to-determine-safety-and-preliminary-anti-tumor-activity

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that...

 hc-wainwright--co-reiterates-buy-on-perspective-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $10 pr...

 perspective-therapeutics-says-first-patient-dosed-in-new-cohort-of-phase-12a-trial-evaluating-the-safety-of-212pbvmt01

First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-ope...

 perspective-therapeutics-names-joel-sendek-cfo-as-juan-graham-departs

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pion...

 perspective-therapeutics-q2-eps-030-inline-sales-290000k-beat-154455k-estimate

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.30) per share which met the analyst consensus estimate. T...

 perspective-therapeutics-to-present-updated-212pbvmt--net-cancer-therapy-data-at-esmo-congress-2025

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pion...

 b-riley-securities-maintains-buy-on-perspective-therapeutics-raises-price-target-to-12

B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target f...

 wedbush-reiterates-outperform-on-perspective-therapeutics-maintains-11-price-target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price...

 reported-saturday-perspective-therapeutics-opens-cohort-3-in-phase-12a-trial-of-212pbvmt--net-for-sstr2-positive-neuroendocrine-tumors-with-20-higher-fixed-dose

[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) th...

 rbc-capital-maintains-outperform-on-perspective-therapeutics-raises-price-target-to-16

RBC Capital analyst Leonid Timashev maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and raises the price ta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION